ReviewThrombosis journal2025
Efficacy and safety of anticoagulation dose reduction for venous thromboembolism prophylaxis in low body weight patients: a systematic review and meta-analysis.
Review in Thrombosis journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thromboembolism (VTE) is a common complication among hospitalized patients, hence VTE prophylaxis is essential. Low body weight patients are at an increased risk of bleeding however there are no guideline recommendations regarding dose adjustment in this population. We performed a meta-analysis to determine whether dose reduction for VTE prophylaxis in low-body weight patients reduces the risk of bleeding, without compromising its efficacy.
methodsWe searched electronic databases from inception to October 2024. We did a random-effects meta-analysis using RevMan 5.4. Data were pooled to obtain a risk ratio (RR) with 95% confidence interval (CI). Heterogeneity and publication bias were assessed with statistic and funnel plot, respectively. Risk of bias was assessed using ROBINS-I and certainty of evidence was assessed using GRADE.
resultsSeven observational studies with 5,575 individuals were included. Pooled analyses revealed no significant difference in risk of total bleeding [RR 0.78, 95% CI 0.48–1.26] and major bleeding [RR 0.62, 95% CI 0.33–1.15] with reduced dose compared to standard dose anticoagulation, however with high heterogeneity (I2 = 64%). Excluding studies with baseline characteristics increasing risk of bleeding in the reduced dose group, sensitivity analysis showed that dose reduction significantly decreases the risk of total [RR 0.49, 95% CI 0.30–0.82] and major bleeding [RR 0.42, 95% CI 0.22–0.80], with low heterogeneity (I = 0). In terms of efficacy, there is not enough evidence to show that anticoagulation dose reduction increases risk of VTE [RR 0.74, 95% CI 0.32–1.73].
conclusionAmong low body weight patients, dose reduction for VTE prophylaxis may reduce risk of bleeding, especially major bleeding, without compromising its efficacy in preventing VTE, hence it can be considered in this population. Randomized controlled trials are needed to further support this recommendation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.